175 related articles for article (PubMed ID: 24076551)
1. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.
Fernández de Larrea C; Jiménez R; Rosiñol L; Giné E; Tovar N; Cibeira MT; Fernández-Avilés F; Martínez C; Rovira M; Bladé J
Bone Marrow Transplant; 2014 Feb; 49(2):223-7. PubMed ID: 24076551
[TBL] [Abstract][Full Text] [Related]
2. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
4. Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
Leng S; Moshier E; Tremblay D; Hu L; Biran N; Barman N; Parekh S; Cho H; Madduri D; Richter J; Barlogie B; Jagannath S; Chari A
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e734-e751. PubMed ID: 32660906
[TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
7. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Doo NW; Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Joyce T; Harrison SJ
Leuk Lymphoma; 2013 Jul; 54(7):1465-72. PubMed ID: 23121086
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC; Zuckerman T; Yeshurun M; Perez G; Magen H; Henig I; Levi I; Shargian L; Trestman S; Rouvio U; Naparstek E; Ganon-Elazar E; Avivi I; Ram R
Ann Hematol; 2017 Feb; 96(2):271-278. PubMed ID: 28039512
[TBL] [Abstract][Full Text] [Related]
10. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
11. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.
Auner HW; Szydlo R; Rone A; Chaidos A; Giles C; Kanfer E; Macdonald DH; Marin D; Milojkovic D; Pavlu J; Apperley JF; Rahemtulla A
Leuk Lymphoma; 2013 Oct; 54(10):2200-4. PubMed ID: 23387937
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
14. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
17. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
[TBL] [Abstract][Full Text] [Related]
18. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
Koreth J; Cutler CS; Djulbegovic B; Behl R; Schlossman RL; Munshi NC; Richardson PG; Anderson KC; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2007 Feb; 13(2):183-96. PubMed ID: 17241924
[TBL] [Abstract][Full Text] [Related]
20. Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Chu TH; Jung SH; Kim K; Lee JH; Mun YC; Bang SM; Yoon DH; Lee HS; Min CK; Lee JJ
Ann Hematol; 2022 Jun; 101(6):1217-1226. PubMed ID: 35445844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
